Compare Jumia Technologies AG - ADR (JMIA) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Organon & Co. Common Stock — how do they compare? Jumia Technologies AG - ADR trades at $5.72 (market cap $789.73M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 4.6× Jumia Technologies AG - ADR's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 29 Days and Organon & Co. Common Stock for 0 Days on average.
| JMIA | OGN | |
|---|---|---|
Market Cap | $789.73M | $3.62B |
Volume | 1,367,204 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $13.81 |
52-Week Low | $5.69 | $5.70 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $755.37M | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $5.79, down 5.24% on the day, amid a bearish technical outlook with all moving averages signaling sell. Fundamentally, the company reported a net loss of $61.55 million in 2025, though revenue grew to $188.93 million and the net loss margin improved to -32.58%. Recent news highlights a $50 million capital raise and progress toward EBITDA breakeven by year-end 2026, per company reports from August 2026.
The outlook is mixed: analyst consensus is bullish with a $12 price target, but high execution risks persist given persistent losses and negative ROE. Investors face volatility from operational cash burn and competitive pressures in African e-commerce, though cost controls and growth initiatives offer potential upside if profitability targets are met.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
